Moving Bispecific Antibodies Into Community Practice: Operational Strategies and Expert Consensus

The rapid evolution of T-cell–engaging therapies has transformed the oncology paradigm, offering highly effective options for patients with hematologic malignancies and solid tumors. While bispecific T-cell engagers (BiTEs) were initially constrained to academic tertiary centers due to severe toxicities like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), there has been a significant shift toward community-based care delivery.

To explore the operationalization of these therapies, CancerNetwork®, alongside AJMC® and Pharmacy Times®, hosted a roundtable discussion featuring multidisciplinary oncology experts. Led by Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, clinical pharmacy manager at the University of Kansas Health System, alongside Ralph Boccia, MD, FACP, medical director and chief executive officer of The Center for Cancer and Blood Disorders, and Lekan Ajayi, PharmD, chief operating officer at Highlands Oncology Group, the panel outlined actionable blueprints for community practice readiness, safety infrastructure, and programmatic sustainability.

Practice Readiness and Care Delivery Models

Data from a national pre-survey highlighted widespread operational heterogeneity across clinical sites. Practices currently administering bispecific antibodies range from purely community-based outpatient clinics to complex hybrid models, academic hubs, and community hospitals.

“There is not a one-size-fits-all [solution], and the right models depend on the patient, the drug, and the system’s ability to then rescue the patient if there is a toxicity that develops,” Mahmoudjafari observed.

Patient volumes vary substantially, with some community clinics treating fewer than 5 patients weekly, while large health systems see 30 to 50. The panelists emphasized that a community practice’s initial workflows must be structured intentionally so they can seamlessly scale alongside climbing patient volumes.

For example, at the University of Kansas Health System, community satellites utilize centralized institutional algorithms and order sets to maintain standardization across geography and separate state pharmacy jurisdictions.

Designing the Outpatient Infrastructure

A central theme of the discussion was the feasibility and safety of executing step-up dosing entirely within the outpatient setting. Historically, product labels suggested inpatient observation during initial ramp-up phases. However, community oncology groups have engineered meticulous protocols to bypass hospitalizations entirely.

At the Center for Cancer and Blood Disorders in Bethesda, MD, patients undergo all step-up dosing as outpatients. Boccia detailed their precise clinical workflow: “We felt that it was important... that we would just not allow everyone in the practice to touch these patients. Only a group of physicians, we call it the... T-cell–engaging team, would be allowed to see these patients.” This dedicated core team, composed of select physicians and advanced practice providers (APPs), handles all internal and external referrals, assessments, and step-up dosing.

To build clinical safety and prevent emergency department (ED) utilization, the panelists recommended several key operational layers:

• Triage Pathways: Boccia highlighted that triage must bypass general clinic staff and front-desk personnel. Dedicated mid-level career clinicians help to manage after-hours calls directly to ensure immediate expert assessment.
• Documentation Redundancy: Standard Operating Procedures (SOPs) should mandate that the treating physician, primary infusion nurse, and nurse manager independently complete dedicated protocol notes validating the presence or absence of CRS at presentation and treatment completion.
• The Caregiver Requirement: Outpatient BiTE administration should be strictly contingent upon the presence of a dedicated caregiver. Both the patient and caregiver must undergo extensive education before initiating therapy.
• Scheduling Conflicts: Clinics should avoid starting step-up or ramp-up doses towards the end of the week to minimize unmonitored weekend complications. However, Boccia and his team offer 24/7 coverage in case medical expertise is needed.

Adverse Event Management and Prophylactic Tocilizumab

The primary toxicities associated with T-cell–engaging mechanisms are CRS and ICANS. While ICANS remains exceedingly rare with bispecific agents compared with chimeric antigen receptor (CAR) T-cell therapies, managing CRS effectively is crucial.

The roundtable exposed a division regarding the use of prophylactic tocilizumab (Actemra), an anti–interleukin-6 receptor antagonist, to mitigate CRS risk. Survey data demonstrated an even split among practitioners.

Mahmoudjafari advocated against routine, universal prophylaxis, stating, “I want to unpack the no-prophylactic tocilizumab [view] as our personal stance. We have left that open-ended for our patients who need it. If we feel like they have high disease burden or may require some tocilizumab, I am not going to stop that, but we are not doing that across the board for everyone. Given that we are a large academic health system, 24/7 coverage and direct admission are [provided] as needed.” Her institutional approach reserves prophylaxis strictly for individuals with high baseline tumor burden or those receiving specific high-risk agents.

Conversely, Boccia’s practice embraces routine upfront prophylaxis for outpatient security. “If you prevent one hospitalization, you’re recouping all of that cost [because] it’s generic; now, the cost is not very high,” he said. He noted that clinical trial data do not clearly identify who will develop severe CRS based on tumor volume alone. When commercial payers reject prophylactic tocilizumab coverage, practices successfully substitute prophylactic dexamethasone and heavy intravenous hydration to optimize outpatient safety.

Beyond CRS, long-term infectious toxicities represent a profound clinical burden, with nearly 80% of patients on bispecific therapies developing subsequent infections. The panel reached a strong consensus recommending universal infection prophylaxis. This includes routine administration of prophylactic intravenous immunoglobulin (IVIG) to combat secondary hypogammaglobulinemia.

Optimizing After-Hours Monitoring

Because toxicities routinely peak outside regular clinic hours, robust remote monitoring frameworks are essential. The experts highlighted a growing reliance on patient-directed toolkits and wearable biometric technology.

Patients treated at outpatient community clinics are frequently sent home with comprehensive monitoring kits containing automated blood pressure cuffs, pulse oximeters, and continuous temperature-tracking patches, such as TempTraq®. “The data suggest that you pick up a fever about 6 hours earlier if you are using this device,” noted Boccia, which provides a critical clinical window to initiate early, low-grade intervention and avert severe CRS progression.

To facilitate rapid clinical access, several participating community practitioners provide patients and caregivers with the direct cell phone numbers of the core T-cell–engaging team. Caregivers are instructed to report vitals and temperatures every 4 hours. If a fever emerges at home, a structured “pill in the pocket” protocol is deployed:

1. Fever detected at home
2. Administer acetaminophen (Tylenol)
3. If fever is unresolved after 1 to 2 hours
   1. Administer protocol dexamethasone and contact dedicated T-cell APP/MD
4. Direct clinic evaluation (avoid standard ED triage if stable)

One of the audience participants highlighted investigating pharmaceutical or industry grants to offset the operational costs of these remote monitoring kits, bridging the financial gap for high-risk oncology populations.

Programmatic Sustainability and Business Metrics

From a financial and administrative perspective, bispecific programs rarely present immediate, highly profitable drug margins. However, the strategic business case for establishing these services within community medicine is undeniable.

Ajayi explained the overarching strategic imperative for community practices to retain these patients rather than referring them to academic centers.

“Community [oncologists] are capable of [giving] these bispecifics in every practice in this country... If you’re not, you’re going to be losing these patients,” Boccia noted. When patients are transferred to tertiary academic systems for step-up dosing, the rate of return to the referring community practice is highly variable and often permanently fractures the local continuity of care.

By engineering internal safety infrastructures and utilizing shared full-time equivalents across existing pharmacy, nursing, and financial navigation staff, community oncology groups can successfully deliver these cutting-edge biologics. This approach preserves the patient-provider relationship, improves patient comfort by keeping care close to home, and positions community practices to adapt to an expanding oncology pipeline as these advanced immunotherapies move into earlier lines of therapy.

Conclusion

The integration of bispecific antibodies into the community setting represents a critical evolution in equitable cancer care delivery. By transitioning step-up dosing from inpatient hospital beds to structured outpatient clinical environments, community practices can successfully improve patient access while preserving regional continuity of care. While concerns regarding toxicities like CRS previously restricted these agents to academic institutions, meticulous planning can overcome these boundaries. Establishing rigorous after-hours workflows, implementing standardized remote biometric monitoring toolkits, and optimizing clinical documentation redundancies provide a reliable foundation for patient safety.

Key Takeaways and Next Steps

• Establish a Dedicated Core T-Cell Team: Community practices should form an internal, specialized clinical group comprising select physicians and APPs to manage patient selection, referrals, and initial dosing cycles rather than opening administration to all general staff.
• Bypass General Triage Workflows: Standard front-desk and generalized nursing triage models are insufficient for triaging patients receiving bispecifics. Implement direct communication lines that immediately route after-hours patient or caregiver alerts to the core “T-cell team.”
• Formalize Infection Prophylaxis Protocols: Due to an infection rate approaching 80%, institutions should standardize the universal administration of prophylactic IVIG and antimicrobial regimens for all patients on bispecific therapies, irrespective of baseline IgG levels.
• Evaluate Local Payer Dynamics for Prophylaxis: Prior to implementing routine prophylactic tocilizumab to suppress outpatient CRS, financial navigation teams must evaluate regional commercial payer landscape behaviors. If local coverage is restricted, clear substitution pathways utilizing prophylactic dexamethasone and intravenous hydration must be codified in the Electronic Medical Record.
• Implement Wearable Remote Biometrics: To facilitate early low-grade intervention and prevent ED admission, equip outpatients with automated blood pressure cuffs and continuous temperature-tracking patches to identify home-based febrile spikes up to 6 hours faster than traditional methods.